News BMS and Infinity aim to overcome triple negative breast canc... BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy in triple negative breast cancer patients.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.